Anthony Stuart, MD
Internal Medicine · Shreveport, LANPI 1508839788
Payments from drug & device makers
Across 263 payments — averaging $14.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$649
- GSK$480
- AstraZeneca$353
- Novo Nordisk$262
- Lilly USA, LLC$258
- AbbVie$207
- plus $2K from 32 others
What the payments were for
- Food & beverage$3,67998%
- Education$782%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 55 | $649 |
| GSK | 41 | $480 |
| AstraZeneca | 17 | $353 |
| Novo Nordisk | 16 | $262 |
| Lilly USA, LLC | 18 | $258 |
| AbbVie(2 entities) | 18 | $207 |
| Johnson & Johnson | 14 | $162 |
| Merck | 12 | $160 |
| Dexcom, Inc. | 7 | $133 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $95 |
| Boehringer Ingelheim | 4 | $86 |
| Corcept Therapeutics | 3 | $79 |
| Phathom Pharmaceuticals, Inc. | 4 | $71 |
| Otsuka America Pharmaceutical, Inc. | 4 | $69 |
| Amgen | 4 | $59 |
| Xeris Pharmaceuticals, Inc. | 3 | $45 |
| Avanir Pharmaceuticals, Inc. | 3 | $45 |
| Novartis | 3 | $41 |
| Bayer | 1 | $41 |
| Insulet Corporation | 2 | $37 |
| Abiomed | 2 | $37 |
| Viatris Specialty LLC | 2 | $36 |
| Daiichi Sankyo Inc. | 2 | $34 |
| Astellas Pharma US Inc | 2 | $32 |
| Abbott | 2 | $31 |
| Mallinckrodt Hospital Products Inc. | 2 | $28 |
| Idorsia Pharmaceuticals US Inc | 2 | $27 |
| E.r. Squibb & Sons, L.L.C. | 2 | $25 |
| Sanofi-aventis U.S. LLC | 2 | $25 |
| Mylan Specialty L.p. | 1 | $22 |
| Vifor Pharma, Inc. | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Verona Pharma, Inc. | 1 | $17 |
| Exact Sciences | 1 | $16 |
| Lundbeck LLC | 1 | $16 |
| Inogen, Inc. | 1 | $14 |
| Shield Therapeutics Inc | 1 | $13 |
| Itamar Medical Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,757 in reported general payments places this provider in the 80th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 221 | $258,192 |
| OzempicSemaglutide | 133 | $136,509 |
| EliquisApixaban | 143 | $135,157 |
| JardianceEmpagliflozin | 87 | $107,396 |
| JanuviaSitagliptin Phosphate | 104 | $104,285 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 112 | $83,795 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 13 | $51,756 |
| Tresiba Flextouch U-100Insulin Degludec | 48 | $47,522 |
| FarxigaDapagliflozin Propanediol | 50 | $45,339 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 12 | $42,609 |
| EntrestoSacubitril/Valsartan | 29 | $41,619 |
| LinzessLinaclotide | 38 | $36,870 |
| CreonLipase/Protease/Amylase | 12 | $31,878 |
| TrulicityDulaglutide | 22 | $29,400 |
| MyrbetriqMirabegron | 25 | $20,870 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $258 | $287,592243 claims |
| Novo NordiskOzempic, Rybelsus | $262 | $154,715149 claims |
| PfizerEliquis, Premarin | $649 | $140,476160 claims |
| MerckJanuvia, Janumet Xr | $160 | $115,520120 claims |
| Boehringer IngelheimJardiance | $86 | $107,39687 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $480 | $89,404124 claims |
| AbbVieLinzess, Creon | $207 | $68,74850 claims |
| AstraZenecaFarxiga, Lokelma | $353 | $51,12870 claims |
| NovartisEntresto | $41 | $41,61929 claims |
| Astellas Pharma US IncMyrbetriq | $32 | $20,87025 claims |
| Johnson & JohnsonXarelto | $162 | $19,39513 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $69 | $16,19011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Shreveport
- Deepika RallaShreveport$261K
- Maliha AgloriaShreveport$181K
- Bharat SachdevaShreveport$165K
- Rajan KhannaShreveport$59K
- Ishak MansiShreveport$53K
- Wendell WallShreveport$25K
- Attila BaloghShreveport$18K
- Ammar AlqaidShreveport$18K
- William SmithNew Orleans$50.5M
- Robert JeanfreauMetairie$13.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.